New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

• New findings from MS PATHS show that treatment with TYSABRI (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus (ocrelizumab)
  
• Real-world data from VUMERITY (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile
• Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab
  

CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life benefits and analyses of extended interval dosing (EID) with TYSABRI (natalizumab) as well as new real-world experience data from VUMERITY (diroximel fumarate). The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS.

“With chronic conditions like MS, where every patient has a different experience with the disease, it is critically important to understand how treatment impacts their daily living and quality of life,” said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. “These data show that the benefits TYSABRI provides in terms of a patient’s quality of life are substantial and that the positive gastrointestinal tolerability profile of VUMERITY can help people with relapsing MS continue with treatment, which is essential to delay its progression.”

Analyses Demonstrate Improved Quality of Life Outcomes with TYSABRI and Further Evaluate Extended Interval Dosing
To better understand clinically meaningful quality of life benefits following treatment with TYSABRI, MS PATHS (Partners Advancing Technology and Health Solutions) researchers analyzed patient reported data on 12 different domains on the Neuro-QoL (Quality of Life in Neurological Disorders) questionnaire such as sleep disturbance, anxiety, fatigue, depression and participation in daily activities. Results included: